Pharmacological interactions between ditazole and anticoagulant drugs.
4,5-Diphenyl-2-bis(2-hydroxyethyl)aminoxazole (ditazole) 200 mg/kg administered orally for 3 days significantly reduced the one-stage prothrombin time in rats treated concomitantly with bishydroxycoumarin (BHC) or warfarin, orally or i.p., as compared with rats given only BHC or warfarin. No significant change occurred in heparin anticoagulant activity when it was administered to rats pretreated with ditazole for 3 days. Warfarin and BHC, in vitro or in vivo, did not influence platelet aggregation or the antiaggregating activity of ditazole. The co-administration of heparin and ditazole enhanced the antiaggregating activity of the two drugs in both in vivo and in vitro tests.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects; D001728:Dicumarol / Q000494:pharmacology; D004347:Drug Interactions; D006487:Hemostasis / Q000187:drug effects*; D006493:Heparin / Q000494:pharmacology; D008297:Male; D010080:Oxazoles / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D011517:Prothrombin Time; D051381:Rats; D014859:Warfarin / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D010080:Oxazoles; D014859:Warfarin; D001728:Dicumarol; D006493:Heparin